Cargando…
Superior efficacy of insulin degludec/liraglutide versus insulin glargine U100 as add‐on to sodium‐glucose co‐transporter‐2 inhibitor therapy: A randomized clinical trial in people with uncontrolled type 2 diabetes
AIM: To investigate the efficacy and safety of insulin degludec/liraglutide (IDegLira) versus insulin glargine 100 units/mL (IGlar U100) as add‐on to sodium‐glucose co‐transporter‐2 (SGLT2) inhibitor therapy. MATERIALS AND METHODS: In this 26‐week, phase IIIb, open‐label, parallel‐group, treat‐to‐ta...
Autores principales: | Philis‐Tsimikas, Athena, Billings, Liana K., Busch, Robert, Portillo, Cristobal Morales, Sahay, Rakesh, Halladin, Natalie, Eggert, Sarah, Begtrup, Kamilla, Harris, Stewart |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593861/ https://www.ncbi.nlm.nih.gov/pubmed/30761720 http://dx.doi.org/10.1111/dom.13666 |
Ejemplares similares
-
Benefits of insulin degludec/liraglutide are maintained even in patients discontinuing sulphonylureas or dipeptidyl peptidase‐4 inhibitors upon initiation of degludec/liraglutide therapy: A post hoc analysis of the DUAL II and DUAL IX trials
por: Janez, Andrej, et al.
Publicado: (2020) -
A Fixed Ratio Combination of Insulin Degludec and Liraglutide (IDegLira) Reduces Glycemic Fluctuation and Brings More Patients with Type 2 Diabetes Within Blood Glucose Target Ranges
por: King, Allen B., et al.
Publicado: (2017) -
The relationship between HbA1c and hypoglycaemia in patients with diabetes treated with insulin degludec versus insulin glargine 100 units/mL
por: Philis‐Tsimikas, Athena, et al.
Publicado: (2020) -
Insulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes: A 1-year, randomized, treat-to-target trial (BEGIN Once Long)
por: Zinman, Bernard, et al.
Publicado: (2012) -
Effect of Insulin Degludec Versus Insulin Glargine U100 on Hypoglycemia in Hispanic Patients With Type 2 Diabetes: Results From the SWITCH 2 Trial
por: Chaykin, Louis, et al.
Publicado: (2019)